spleen, 0.200.26%)
Many anabolic, growth, and metabolic effects are mediated partly by IGF-1
When speaking to your GP or specialist, consider raising the following: Your weight management goals and what evidence-based options are available Any supplements or compounds you are currently using or considering Symptoms you may already be experiencing that could indicate metabolic or hormonal imbalance Your eligibility for NHS-funded obesity treatments , including approved GLP-1 therapies Healthcare professionals are not there to judge but to help you make informed, safe decisions
If you are seeing satisfactory weight loss results at 10 mg or 12.5 mg with tolerable side effects, there may be no clinical reason to escalate further
Trial exclusion patterns Phase 2 and Phase 3 retatrutide trials commonly excluded participants with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), severe gastroparesis, recent major cardiovascular events, severe kidney impairment, type 1 diabetes (in the obesity studies), and pregnancy or breastfeeding
